News

Filter

Current filters:

BiosimilarsRemicade

1 to 9 of 13 results

Hospira’s biosimilar Inflectra comparable to Remicade in IBD treatment

Hospira’s biosimilar Inflectra comparable to Remicade in IBD treatment

19-02-2015

Positive data have been presented today on the use of Hospira's Inflectra (infliximab), the world's first…

BiosimilarsBiotechnologyGastro-intestinalsHospiraInflectraJohnson & JohnsonMerck & CoRemicadeResearch

New phase of MAb biosimilars opportunities in Japan

New phase of MAb biosimilars opportunities in Japan

21-01-2015

The launch of Remicade (infliximab, from Johnson & Johnson) biosimilar in December 2014 in the Japan…

BiosimilarserythropoietinGenericsJapanMarkets & MarketingRegulationRemicade

PHARMAC secures significant savings for New Zealand’s DHBs on biologic drug

04-12-2014

A new agreement for a high cost biologic drug will yield considerable savings for District Health Boards…

Anti-Arthritics/RheumaticsBiosimilarsBiotechnologyinfliximabJohnson & JohnsonNew ZealandPricingRemicade

Nippon Kayaku launches biosimilar Remicade in Japan

Nippon Kayaku launches biosimilar Remicade in Japan

01-12-2014

Japanese drugmaker Nippon Kayaku has launched the sale of Infliximab BS for IV Infusion 100mg, a biosimilar…

Anti-Arthritics/RheumaticsBiosimilarsGenericsinfliximabJapanJohnson & JohnsonMarkets & MarketingNippon KayakuRemicade

EPIRUS and Livzon Mabpharm to develop biosimilars for China

EPIRUS and Livzon Mabpharm to develop biosimilars for China

25-09-2014

EPIRUS Biopharmaceuticals has signed a royalty-bearing, multi-product collaboration agreement with Livzon…

Anti-Arthritics/RheumaticsBiosimilarsBOW015ChinaEPIRUS BiopharmaceuticalsGastro-intestinalsGenericsLicensingLivzon MabpharmRemicadeResearch

Opportunity for emerging agents in Crohn’s disease, report finds

Opportunity for emerging agents in Crohn’s disease, report finds

18-09-2014

New research from Decision Resources Group has found that only a small proportion of patients with Crohn's…

Anti-Arthritics/RheumaticsBiosimilarsEntyvioHumiraPharmaceuticalRemicadeResearchStelaraUSAXeljanz

Celltrion files for US FDA approval of Remsima biosimilar

Celltrion files for US FDA approval of Remsima biosimilar

13-08-2014

South Korean biopharmaceutical firm Celltrion says it has completed the filing procedure to obtain US…

BiosimilarsBiotechnologyCellTrionClinical researchInflammatory diseasesinfliximabJanssen BiotechJohnson & JohnsonPatentsRegulationRemicadeRemsimaUSA

1 to 9 of 13 results

Back to top